Skip to main
CRBP

CRBP Stock Forecast & Price Target

CRBP Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corbus Pharmaceuticals is expected to continue its positive momentum with promising data from their pipeline, including the ongoing CANYON-1 trial and the upcoming TEMPO-1 trial evaluating CRB-701 in second-line oropharyngeal squamous cell carcinoma and CRB-913 in obesity. Additionally, the company remains financially stable with $117.9M in cash, cash equivalents, and investments as of June 30, 2026 to fund current operations and planned expenditures into 2028. However, there are risks associated with any clinical trials, potential competition from other companies, and the need for additional funding that may impact the company's future success.

Bears say

Corbus Pharmaceuticals is facing significant challenges with its development pipeline, as its ADC CRB-701 needs to show more significant results in larger trials and its drug CRB-913 needs to demonstrate an acceptable therapeutic window. Additionally, the company's focus on oncology and obesity may limit its potential market, as it competes with more established and effective treatments in these fields. The company's financials are also concerning, as it has yet to generate significant revenue and investors may lose patience if clinical trials do not produce successful results.

CRBP has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast

Analysts have given CRBP a Buy based on their latest research and market trends.

According to 7 analysts, CRBP has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corbus Pharmaceuticals Holdings (CRBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.